Page 5 of 7 SEC Filing
13D
CUSIP No. 91911K102 Page 5
This Amendment No. 4 to Schedule 13D (this Amendment No. 4) amends and
supplements the statement on Schedule 13D (the Original Schedule 13D), filed on March 25, 2015 (the Original Schedule 13D, as amended and supplemented through the date of this Amendment No. 4, the Schedule
13D), by Pershing Square Capital Management, L.P., a Delaware limited partnership (Pershing Square); PS Management GP, LLC, a Delaware limited liability company (PS Management); and William A. Ackman,
a citizen of the United States of America (together with Pershing Square and PS Management, the Reporting Persons), relating to the common stock, no par value (the Common Stock), of Valeant Pharmaceuticals
International, Inc., a corporation continued under the laws of British Columbia, Canada (the Issuer). Capitalized terms used but not defined in this amendment shall have the meanings set forth in the Schedule 13D.
Except as specifically amended by this Amendment No. 4, the Schedule 13D is unchanged.
ITEM 4. PURPOSE OF TRANSACTION
Item 4 of the Schedule 13D is hereby amended and
supplemented to add the following information:
On March 9, 2016, the Issuer announced that its board of directors (the
Board) appointed Stephen Fraidin, Vice Chairman of Pershing Square, as well as Fred Eshelman and Thomas W. Ross, Jr., as independent directors, effective immediately.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
Item 6 of the Schedule 13D is hereby amended and supplemented to add the following information:
In connection with Mr. Fraidins appointment to the Issuers Board, the Issuer entered into an information sharing agreement
with Pershing Square, on behalf of itself and the Pershing Square Funds, and Mr. Fraidin that is filed as Exhibit 99.9. That agreement is incorporated by reference into this Item 6 as if restated in full herein.
ITEM 7. MATERIAL TO BE FILED AS AN EXHIBIT
Item 7 of Schedule 13D is hereby amended and
supplemented to add the following exhibit:
Exhibit 99.9 Information Sharing Agreement.
Follow Bausch Health Companies Inc. (NYSE:BHC)
Follow Bausch Health Companies Inc. (NYSE:BHC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
13D
| CUSIP No. 91911K102 | Page 5 |
This Amendment No. 4 to Schedule 13D (this Amendment No. 4) amends and
supplements the statement on Schedule 13D (the Original Schedule 13D), filed on March 25, 2015 (the Original Schedule 13D, as amended and supplemented through the date of this Amendment No. 4, the Schedule
13D), by Pershing Square Capital Management, L.P., a Delaware limited partnership (Pershing Square); PS Management GP, LLC, a Delaware limited liability company (PS Management); and William A. Ackman,
a citizen of the United States of America (together with Pershing Square and PS Management, the Reporting Persons), relating to the common stock, no par value (the Common Stock), of Valeant Pharmaceuticals
International, Inc., a corporation continued under the laws of British Columbia, Canada (the Issuer). Capitalized terms used but not defined in this amendment shall have the meanings set forth in the Schedule 13D.
Except as specifically amended by this Amendment No. 4, the Schedule 13D is unchanged.
| ITEM 4. | PURPOSE OF TRANSACTION |
Item 4 of the Schedule 13D is hereby amended and
supplemented to add the following information:
On March 9, 2016, the Issuer announced that its board of directors (the
Board) appointed Stephen Fraidin, Vice Chairman of Pershing Square, as well as Fred Eshelman and Thomas W. Ross, Jr., as independent directors, effective immediately.
| ITEM 6. | CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER |
Item 6 of the Schedule 13D is hereby amended and supplemented to add the following information:
In connection with Mr. Fraidins appointment to the Issuers Board, the Issuer entered into an information sharing agreement
with Pershing Square, on behalf of itself and the Pershing Square Funds, and Mr. Fraidin that is filed as Exhibit 99.9. That agreement is incorporated by reference into this Item 6 as if restated in full herein.
| ITEM 7. | MATERIAL TO BE FILED AS AN EXHIBIT |
Item 7 of Schedule 13D is hereby amended and
supplemented to add the following exhibit:
| Exhibit 99.9 | Information Sharing Agreement. |
